Welcome to our dedicated page for Kkr & Co news (Ticker: KKR), a resource for investors and traders seeking the latest updates and insights on Kkr & Co stock.
KKR & Co. Inc. (NYSE: KKR) is a global investment firm active across alternative asset management, capital markets and insurance solutions, and its news flow reflects this breadth. Press releases describe KKR-sponsored funds investing in private equity, credit and real assets, alongside insurance subsidiaries that offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group.
Recent KKR news highlights activity in private credit, infrastructure, real estate, digital infrastructure and transportation. For example, KKR announced the completion of a fundraise for KKR Asia Credit Opportunities Fund II and related accounts, focused on privately originated performing credit investments in Asia Pacific. The firm also reported a strategic partnership with RWE to develop UK offshore wind projects, illustrating its participation in energy transition and renewables infrastructure.
Other releases describe additional equity commitments to a European data center platform, the acquisition of a large logistics facility in Korea, and a strategic partnership to build a European rail leasing platform through an investment in Green Mobility Partners. KKR also issues updates on monetization activity, earnings release dates and fund distribution announcements, such as those related to KKR Income Opportunities Fund.
Investors and observers using this news page can review KKR’s official announcements on transactions, fund launches, capital raises, governance developments and financial disclosures. The coverage provides context on how KKR’s funds and subsidiaries operate across private equity, credit, real assets and insurance, and how the firm positions itself in themes such as private credit, digital infrastructure and the energy transition.
KKR (NYSE:KKR) has announced an agreement to sell its controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) to Torrent Pharmaceuticals in a significant two-phase transaction valued at INR 25,689 crores (on fully diluted basis).
The transaction structure includes: 1) Acquisition of 46.39% equity stake through a Share Purchase Agreement at INR 11,917 crores (INR 1,600 per share), followed by a mandatory open offer for up to 26% additional shares at INR 1,639.18 per share. 2) Merger between Torrent and JB Pharma where shareholders will receive 51 Torrent shares for every 100 JB Pharma shares.
The strategic acquisition strengthens Torrent's presence in the Indian pharmaceutical market, particularly in chronic segments, while providing entry into new areas like ophthalmology and CDMO capabilities. The deal requires approvals from various regulatory bodies including SEBI, Stock Exchanges, CCI, and NCLT.